11 / 21
Page 41
December 06-07 , 2018
Amsterdam, Nether l ands
Journal of Neuropsychiatry
ISSN: 2471-8548
Alzheimer’s and Dementia 2018
1 3
t h
W o r l d c o n g r e s s o n
Alzheimer’s and Dementia
H
sp70 and other molecular chaperones function as a complex neuroprotective system, which fails in the brains of aged
people and Alzheimer disease (AD)-type neuropathologies. It was demonstrated that intranasally injected exogenous Hsp70
(eHsp70) effectively bypassed the blood-brain barrier and penetrates brain regions of the model animals. It was shown that
chronic administration of eHsp70 decreases beta-amyloid level and the number of Aβ-plaques in two mouse models of AD. In
both cases, eHsp70 restored learning and memory parameters as well as functional state of neurons. Characteristically, eHsp70
treatment increased synaptophysin level and protects neurons in brain areas most affected in AD patients such as hippocampus
and neocortex. It was also demonstrated that eHsp70 can promote longevity and life quality in male mice. The eHsp70 treatment
decreased accumulation of aging marker lipofuscin and modulates the activity of UPS by increasing expression of several
proteasome subunits including immunoproteasome subunit β5i. Deep sequencing studies exploring mice of brain regions of
AD-model ̶ 5XFAD different age groups treated with eHsp70 revealed candidate genes and signal pathways probably underlying
beneficial effects of eHsp70 treatment. Taken together, our findings established intranasal administration of exogenous human
Hsp70 as a practical therapeutic approach for the treatment of various neurodegenerative diseases and aging.
misha672011@yahoo.comIntranasal administration of Hsp70: molecular and
therapeutic consequences
Evgen’ev M B
1,2
, Garbuz D G
1
, Morozov AV
1
and Bobkova N V
2
1
Engelhardt Institute of Molecular Biology, Russia
2
Institute of Cell Biophysics-RAS, Russia
J Neurol Neurosci 2018, Volume: 2
DOI: 10.21767/2471-8548-C1-003